GlassScriptPhysician profile
Shelly Ahn Im
NPI 1740496470
$732.39
in general payments reported to CMS, 2019-2025
14 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.42 · 2024: $169 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.97 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $184.86 | 2024-2025 | Wegovy |
| Mannkind Corporation | $112.35 | 2025 | |
| Xeris Pharmaceuticals, INC. | $76.94 | 2025 | Recorlev |
| Lilly USA, LLC | $67.64 | 2022-2025 | Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $53.37 | 2024-2025 | |
| Antares Pharma, INC. | $44.34 | 2025 | Xyosted |
| Ascendis Pharma Endocrinology INC | $38.82 | 2025 | Yorvipath |
| Radius Health, INC. | $30.09 | 2025 | Tymlos |
| Corcept Therapeutics | $25.07 | 2025 | Korlym |
| Recordati_rare_diseases_inc. | $23.77 | 2025 | Isturisa |
| Neurocrine Biosciences, INC. | $23.53 | 2025 | |
| Astellas Pharma US INC | $21.24 | 2025 | Veozah |
| Almatica Pharma LLC | $15.58 | 2024 | Teriparatide |
| Currax Pharmaceuticals LLC | $14.79 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Im listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.